Category: Drug Safety Alerts
-
Two More Medical Studies Show Increased Risk Of Blood Clots With Use Of YAZ, Yasmin, And Ocella
Researchers Find Drospirenone (DRSP) Containing Birth Control Pills Increased Risk Of Pulmonary Embolism (PE) And Deep Vein Thrombosis (DVT) (Posted by Tom Lamb at DrugInjuryWatch.com) New research published online in October 2011 by the…
-
Ortho Evra Update: October 2011 FDA Study Finds Increased Risk Of Blood Clot Side Effects Deep Vein Thrombosis & Pulmonary Embolism
Given These New FDA Drug Safety Findings About Ortho Evra, What Will Two Advisory Committees Do At Joint Meeting On December 9, 2011? (Posted by Tom Lamb at DrugInjuryWatch.com) On October 27, 2011 the FDA…
-
YAZ / Yasmin / Ocella Update: October 2011 FDA Study Finds Increased Risk Of Blood Clot Side Effects Like DVT, PE, Stroke, And Heart Attack
Safety Study Findings About Drospirenone (DRSP) Birth Control Pills Will Be On The Agenda For FDA Advisory Committees At Joint Meeting In December 2011 (Posted by Tom Lamb at DrugInjuryWatch.com) On October 27, 2011 the FDA…
-
NuvaRing Update: October 2011 FDA Study Finds Increased Risk Of Pulmonary Embolism (PE) And Deep Vein Thrombosis (DVT)
Will NuvaRing Safety Study Findings Be Addressed By FDA Advisory Committees At Joint Meeting In December 2011? (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: "October 2013 NuvaRing Label Change: Warnings And Precautions Section…
-
New Heart Drug Pradaxa May Be Sending “Early” Drug Safety Signals
ISMP QuarterWatch 2010 4th Quarter: Hemorrhages And Thromboembolic Events Have Been Reported To FDA (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: "Boehringer says about 260 deaths related to Pradaxa" (11/12/11, Reuters) FRANKFURT Nov 12…
-
European Medicines Agency (EMA) Recommends Multaq Use Should Be Restricted For Safety Reasons
EMA Cites The Increased Risks Of Liver Injury, Lung Side Effects, And Cardiovascular Adverse Events (Posted by Tom Lamb at DrugInjuryWatch.com) In late September 2011 the European Medicines Agency (EMA) recommended that the use…
-
Reports Of Male Breast Cancer Associated With The Use Of Propecia And Proscar
Recent Label Change For These Drugs Made In Canada But Not In U.S., Yet (Posted by Tom Lamb at DrugInjuryWatch.com)On August 4, 2011 Health Canada issued this Information Update, "Finasteride (Propecia, Proscar): Potential rare risk…
-
Increased Risk Of Bladder Cancer Warning Added To Actos Label By Takeda Announced In August 2011
European Drug Regulator EMA Recommended New Actos Contra-Indications And Warnings In July 2011 (Posted by Tom Lamb at DrugInjuryWatch.com) _____________________________________________________________________ UPDATE: "European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer" …
-
Multaq Cardiovascular Deaths Overshadow Earlier Liver Injury Concerns For Drug Regulators
FDA Now Looking At Two-Fold Increase In CV Deaths, Strokes, And Heart Failure Hospitalizations From PALLAS Study Data (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: "Multaq (dronedarone) – Information on Increase in Heart-Related…
-
Multaq Update: European Safety Review Expanded To Cardiovascular Side Effects Risk In July 2011
EMA And FDA Already Had Sanofi Issue A "Dear Doctor" Letter About Liver Failure In January 2011 (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: The FDA announced on July 21, 2011 that it…